Top

Journal of Experimental & Clinical Cancer Research

Published in:

01-12-2021 | Sulfasalazine | Research

PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells

Authors: Ji Hyeon You, Jaewang Lee, Jong-Lyel Roh

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Background

Progesterone receptor membrane component 1 (PGRMC1) is a heme-binding protein inducing dimerization with cytochrome P450, which mediates chemoresistance. Increased PGRMC1 expression is found in multiple types of resistant cancers, but the role of PGRMC1 in the ferroptosis of cancer cells remains unrevealed. Therefore, we examined the role of PGRMC1 in promoting ferroptosis in paclitaxel-tolerant persister cancer cells (PCC).

Methods

The effects of ferroptosis inducers and PGRMC1 gene silencing/overexpression were tested on head and neck cancer (HNC) cell lines and mouse tumor xenograft models. The results were analyzed about cell viability, death, lipid ROS and iron production, mRNA/protein expression and interaction, and lipid assays.

Results

PCC had more free fatty acids, lipid droplets, and fatty acid oxidation (FAO) than their parental cells. PCC was highly sensitive to inhibitors of system xc⁻ cystine/glutamate antiporter (xCT), such as erastin, sulfasalazine, and cyst(e)ine deprivation, but less sensitive to (1S,3R)-RSL3. PGRMC1 silencing in PCC reduced ferroptosis sensitivity by xCT inhibitors, and PGRMC1 overexpression in parental cells increased ferroptosis by xCT inhibitors. Lipid droplets were degraded along with autophagy induction and autophagosome formation by erastin treatment in PCC. Lipophagy was accompanied by increased tubulin detyrosination, which was increased by SIRT1 activation but decreased by SIRT1 inhibition. FAO and lipophagy were also promoted by the interaction between lipid droplets and mitochondria.

Conclusion

PGRMC1 expression increased FAO and ferroptosis sensitivity from in vivo mice experiments. Our data suggest that PGRMC1 promotes ferroptosis by xCT inhibition in PCC.

Available only for authorised users

Mullard A. Stemming the tide of drug resistance in cancer. Nat Rev Drug Discov. 2020;19:221–3. https://doi.org/10.1038/d41573-020-00050-y.CrossRefPubMed

Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69–80. https://doi.org/10.1016/j.cell.2010.02.027.CrossRefPubMedPubMedCentral

Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov. 2020;19:39–56. https://doi.org/10.1038/s41573-019-0044-1.CrossRefPubMed

Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547:453–7. https://doi.org/10.1038/nature23007.CrossRefPubMedPubMedCentral

Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551:247–50. https://doi.org/10.1038/nature24297.CrossRefPubMedPubMedCentral

You JH, Lee J, Roh JL. Mitochondrial pyruvate carrier 1 regulates ferroptosis in drug-tolerant persister head and neck cancer cells via epithelial-mesenchymal transition. Cancer Lett. 2021;507:40–54. https://doi.org/10.1016/j.canlet.2021.03.013.CrossRefPubMed

Angeli JPF, Shah R, Pratt DA, Conrad M. Ferroptosis inhibition: mechanisms and opportunities. Trends Pharmacol Sci. 2017;38:489–98. https://doi.org/10.1016/j.tips.2017.02.005.CrossRefPubMed

Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72. https://doi.org/10.1016/j.cell.2012.03.042.CrossRefPubMedPubMedCentral

Feng H, Stockwell BR. Unsolved mysteries: how does lipid peroxidation cause ferroptosis? PLoS Biol. 2018;16:e2006203. https://doi.org/10.1371/journal.pbio.2006203.CrossRefPubMedPubMedCentral

10.

Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death Nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273–85. https://doi.org/10.1016/j.cell.2017.09.021.CrossRefPubMedPubMedCentral

11.

Hughes AL, Powell DW, Bard M, Eckstein J, Barbuch R, Link AJ, et al. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab. 2007;5:143–9. https://doi.org/10.1016/j.cmet.2006.12.009.CrossRefPubMed

12.

Cahill MA, Jazayeri JA, Catalano SM, Toyokuni S, Kovacevic Z, Richardson DR. The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biology. Biochim Biophys Acta. 2016;1866:339–49. https://doi.org/10.1016/j.bbcan.2016.07.004.CrossRefPubMed

13.

Crudden G, Loesel R, Craven RJ. Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors. Tumour Biol. 2005;26:142–6. https://doi.org/10.1159/000086485.CrossRefPubMed

14.

Mir SU, Schwarze SR, Jin L, Zhang J, Friend W, Miriyala S, et al. Progesterone receptor membrane component 1/Sigma-2 receptor associates with MAP1LC3B and promotes autophagy. Autophagy. 2013;9:1566–78. https://doi.org/10.4161/auto.25889.CrossRefPubMed

15.

Rohe HJ, Ahmed IS, Twist KE, Craven RJ. PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol Ther. 2009;121:14–9. https://doi.org/10.1016/j.pharmthera.2008.09.006.CrossRefPubMed

16.

Kim SY, Chu KC, Lee HR, Lee KS, Carey TE. Establishment and characterization of nine new head and neck cancer cell lines. Acta Otolaryngol. 1997;117:775–84. https://doi.org/10.3109/00016489709113477.CrossRefPubMed

17.

Garcés R, Mancha M. One-step lipid extraction and fatty acid methyl esters preparation from fresh plant tissues. Anal Biochem. 1993;211:139–43. https://doi.org/10.1006/abio.1993.1244.CrossRefPubMed

18.

Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer Cell. 2011;19:387–400. https://doi.org/10.1016/j.ccr.2011.01.038.CrossRefPubMed

19.

Ojima I, Lichtenthal B, Lee S, Wang C, Wang X. Taxane anti-cancer agents: a patent perspective. Expert Opin Ther Patents. 2016;26:1–20. https://doi.org/10.1517/13543776.2016.1111872.CrossRef

20.

Qu Q, Zeng F, Liu X, Wang QJ, Deng F. Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. Cell Death Dis. 2016;7:e2226. https://doi.org/10.1038/cddis.2016.132.CrossRefPubMedPubMedCentral

21.

Gutierrez A, Pan L, Groen RW, Baleydier F, Kentsis A, Marineau J, et al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest. 2014;124:644–55. https://doi.org/10.1172/jci65093.CrossRefPubMedPubMedCentral

22.

Asperger H, Stamm N, Gierke B, Pawlak M, Hofmann U, Zanger UM, et al. Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression. Breast Cancer Res. 2020;22:75. https://doi.org/10.1186/s13058-020-01312-8.CrossRefPubMedPubMedCentral

23.

Lodde V, Peluso JJ. A novel role for progesterone and progesterone receptor membrane component 1 in regulating spindle microtubule stability during rat and human ovarian cell mitosis. Biol Reprod. 2011;84:715–22. https://doi.org/10.1095/biolreprod.110.088385.CrossRefPubMed

24.

Fonrose X, Ausseil F, Soleilhac E, Masson V, David B, Pouny I, et al. Parthenolide inhibits tubulin carboxypeptidase activity. Cancer Res. 2007;67:3371–8. https://doi.org/10.1158/0008-5472.can-06-3732.CrossRefPubMed

25.

Thejer BM, Adhikary PP, Teakel SL, Fang J, Weston PA, Gurusinghe S, et al. PGRMC1 effects on metabolism, genomic mutation and CpG methylation imply crucial roles in animal biology and disease. BMC Mol Cell Biol. 2020;21:26. https://doi.org/10.1186/s12860-020-00268-z.CrossRefPubMedPubMedCentral

26.

Sathyanarayan A, Mashek MT, Mashek DG. ATGL promotes autophagy/lipophagy via SIRT1 to control hepatic lipid droplet catabolism. Cell Rep. 2017;19:1–9. https://doi.org/10.1016/j.celrep.2017.03.026.CrossRefPubMedPubMedCentral

27.

Herms A, Bosch M, Reddy BJ, Schieber NL, Fajardo A, Rupérez C, et al. AMPK activation promotes lipid droplet dispersion on detyrosinated microtubules to increase mitochondrial fatty acid oxidation. Nat Commun. 2015;6:7176. https://doi.org/10.1038/ncomms8176.CrossRefPubMed

28.

Cui L, Liu P. Two types of contact between lipid droplets and mitochondria. Front Cell Dev Biol. 2020;8:618322. https://doi.org/10.3389/fcell.2020.618322.CrossRefPubMedPubMedCentral

29.

Stewart DA, Winnike JH, McRitchie SL, Clark RF, Pathmasiri WW, Sumner SJ. Metabolomics analysis of hormone-responsive and triple-negative breast cancer cell responses to paclitaxel identify key metabolic differences. J Proteome Res. 2016;15:3225–40. https://doi.org/10.1021/acs.jproteome.6b00430.CrossRefPubMedPubMedCentral

30.

Cao Y. Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest. 2019;129:3006–17. https://doi.org/10.1172/jci127201.CrossRefPubMedPubMedCentral

31.

Barbuti AM, Chen ZS. Paclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapy. Cancers. 2015;7:2360–71. https://doi.org/10.3390/cancers7040897.CrossRefPubMedPubMedCentral

32.

Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003;22:7280–95. https://doi.org/10.1038/sj.onc.1206934.CrossRefPubMedPubMedCentral

33.

Friel AM, Zhang L, Pru CA, Clark NC, McCallum ML, Blok LJ, et al. Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors. Cancer Lett. 2015;356:434–42. https://doi.org/10.1016/j.canlet.2014.09.036.CrossRefPubMed

34.

Schroeder B, Schulze RJ, Weller SG, Sletten AC, Casey CA, McNiven MA. The small GTPase Rab7 as a central regulator of hepatocellular lipophagy. Hepatology (Baltimore, Md). 2015;61:1896–907. https://doi.org/10.1002/hep.27667.CrossRef

35.

Rambold AS, Cohen S, Lippincott-Schwartz J. Fatty acid trafficking in starved cells: regulation by lipid droplet lipolysis, autophagy, and mitochondrial fusion dynamics. Dev Cell. 2015;32:678–92. https://doi.org/10.1016/j.devcel.2015.01.029.CrossRefPubMedPubMedCentral

36.

Benador IY, Veliova M, Liesa M, Shirihai OS. Mitochondria bound to lipid droplets: where mitochondrial dynamics regulate lipid storage and utilization. Cell Metab. 2019;29:827–35. https://doi.org/10.1016/j.cmet.2019.02.011.CrossRefPubMedPubMedCentral

37.

Mohan N, Sorokina EM, Verdeny IV, Alvarez AS, Lakadamyali M. Detyrosinated microtubules spatially constrain lysosomes facilitating lysosome-autophagosome fusion. J Cell Biol. 2019;218:632–43. https://doi.org/10.1083/jcb.201807124.CrossRefPubMedPubMedCentral

38.

Lee N, Carlisle AE, Peppers A, Park SJ, Doshi MB, Spears ME, et al. xCT-driven expression of GPX4 determines sensitivity of breast cancer cells to ferroptosis inducers. Antioxidants (Basel, Switzerland). 2021;10. https://doi.org/10.3390/antiox10020317.

Title: PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells
Authors: Ji Hyeon You
Jaewang Lee
Jong-Lyel Roh
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Sulfasalazine
Progesterone
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-02168-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Molecular features and vulnerabilities of recurrent chordomas

Correction to: microRNA-193a stimulates pancreatic cancer cell repopulation and metastasis through modulating TGF-β2/TGF-βRIII signalings

SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia

KLF5-induced BBOX1-AS1 contributes to cell malignant phenotypes in non-small cell lung cancer via sponging miR-27a-5p to up-regulate MELK and activate FAK signaling pathway

Pyroptosis: a new paradigm of cell death for fighting against cancer

Correction to: Pyroptosis: a new paradigm of cell death for fighting against cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer